Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients - Summary - MDSpire

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients

  • By

  • May Ee Png

  • Victoria Harris

  • Ly-Mee Yu

  • Paul Little

  • F. D. Richard Hobbs

  • Christopher C. Butler

  • Stavros Petrou

  • PANORAMIC Trial Collaborative Group

  • Oghenekome A Gbinigie

  • Najib M Rahman

  • Gail Hayward

  • Duncan B Richards

  • Jienchi Dorward

  • David M Lowe

  • Joseph F Standing

  • Judith Breuer

  • Saye Khoo

  • Kerenza Hood

  • Jonathan S Nguyen-Van-Tam

  • Mahendra G Patel

  • Benjamin R Saville

  • Joe Marion

  • Nick Francis

  • Nicholas P B Thomas

  • Philip Evans

  • Melissa Dobson

  • Jane Holmes

  • Mark Lown

  • Oliver van Hecke

  • Michelle A Detry

  • Christina T Saunders

  • Mark Fitzgerald

  • Nicholas S Berry

  • Sam Mort

  • Bhautesh D Jani

  • Nigel D Hart

  • Haroon Ahmed

  • Daniel Butler

  • Micheal McKenna

  • Lucy Cureton

  • Meena Patil

  • Monique Andersson

  • Clare Bateman

  • Jennifer C Davies

  • Andrew Ustianowski

  • Andrew Carson Stevens

  • May 6, 2026

  • 0 min

Share

Objective:

To conduct a trial-based economic evaluation of nirmatrelvir-ritonavir compared to usual care for high-risk COVID-19 patients within the context of the UK healthcare system.

Key Findings:
  • Nirmatrelvir-ritonavir significantly reduced hospitalization and death risk by 89% when administered early. Cost-effectiveness varied by vaccination status, with mixed findings on its economic viability for vaccinated individuals. The evaluation followed CHEERS guidelines, which ensure transparency and relevance for decision-makers, and was conducted under ethical approvals.
Interpretation:

Nirmatrelvir-ritonavir is a cost-effective treatment option for high-risk COVID-19 patients, particularly when initiated early, with significant implications for clinical practice.

Limitations:
  • Previous evaluations were nonrandomized and may not generalize across different healthcare settings, particularly those with varying financing arrangements and population characteristics.
Conclusion:

The study supports the use of nirmatrelvir-ritonavir in high-risk COVID-19 patients, highlighting its cost-effectiveness and potential to reduce severe outcomes, especially when treatment is initiated early.

Original Source(s)

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients

  • by May Ee Png, Victoria Harris, Ly-Mee Yu, Paul Little, F. D. Richard Hobbs, Christopher C. Butler, Stavros Petrou, PANORAMIC Trial Collaborative Group, Oghenekome A Gbinigie, Najib M Rahman, Gail Hayward, Duncan B Richards, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Kerenza Hood, Jonathan S Nguyen-Van-Tam, Mahendra G Patel, Benjamin R Saville, Joe Marion, Nick Francis, Nicholas P B Thomas, Philip Evans, Melissa Dobson, Jane Holmes, Mark Lown, Oliver van Hecke, Michelle A Detry, Christina T Saunders, Mark Fitzgerald, Nicholas S Berry, Sam Mort, Bhautesh D Jani, Nigel D Hart, Haroon Ahmed, Daniel Butler, Micheal McKenna, Lucy Cureton, Meena Patil, Monique Andersson, Clare Bateman, Jennifer C Davies, Andrew Ustianowski, Andrew Carson Stevens

  • May 6, 2026

Related Content

Acute liver failure and secondary TMA-like phenomenon following SARS-CoV-2 and Mycoplasma pneumoniae co-detection in a child: a case report

Raman Spectroscopy Moves to the Front Line of Pandemic Preparedness

Comprehensive review highlights label-free viral detection – and the hurdles to real-world deployment

  • May 7, 2026

  • 2 min
Early ICU Rehab Backed, With Caveats

Invited narrative review supports early, interprofessional rehabilitation across the ICU recovery continuum while emphasizing heterogeneous evidence and inconsistent implementation worldwide.